Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial
about
Cardiac biomarkers: new tools for heart failure managementState of the Art: Newer biomarkers in heart failureThe association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study.The Usefulness of the Delta Neutrophil Index for Predicting Superimposed Pneumonia in Patients with Acute Decompensated Heart Failure in the Emergency Department.Procalcitonin-guided diagnosis and antibiotic stewardship revisited.Cardiorenal biomarkers in acute heart failure.The emerging role of biomarkers and bio-impedance in evaluating hydration status in patients with acute heart failure.Treatment for chronic heart failure in the elderly: current practice and problems.Heart failure biomarkers.Heart failure highlights in 2012-2013.Biomarkers for risk prediction in acute decompensated heart failure.Beyond cardiac troponin: recent advances in the development of alternative biomarkers for cardiovascular disease.Prehospital triage of patients suffering severe dyspnoea using N-terminal pro-brain natriuretic peptide, the PreBNP trial: a randomised controlled clinical trial.European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care.Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance.Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESCEuropean Society of Cardiology - Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department.Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).The role of procalcitonin in acute heart failure patients.Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study.Should procalcitonin be measured routinely in acute decompensated heart failure?Acute heart failure facts and numbers: acute heart failure populationsHeart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challengesRationale and design of the IMPACT EU-trial: improve management of heart failure with procalcitonin biomarkers in cardiology (BIC)-18.Procalcitonin in heart failure: hic et nunc.Prognostic value of PCT, copeptin, MR-proADM, MR-proANP and CT-proET-1 for severe acute dyspnea in the emergency department: the BIODINER study.[Point-of-care testing in preclinical emergency medicine].Is there a C-reactive protein value beyond which one should consider infection as the cause of acute heart failure?Acute Heart Failure Management.Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
P2860
Q26991726-59AB6754-BC2D-4BCD-8540-980B4DC9F266Q27027899-31179088-BA96-41A3-9C5D-D44FEB140475Q35895518-71B8BDC9-AE90-45AD-9C44-2BBFE499FCFCQ36147314-812D37A8-570E-44BB-B710-CAE0555F50F6Q36257991-3465ADBD-4145-4A9B-9208-0F2610C1414AQ36313675-D058D84D-80ED-4EEA-A2D1-B00115120348Q38044782-EC52A022-F542-4B00-9FBE-78C4408FED0FQ38057693-153D89ED-55F0-470A-B44F-482D93AA2F4EQ38100647-F8279E5B-2A35-47A4-A171-45986CE461D5Q38182010-891A39BF-AD03-49F2-A201-2975DABA35C7Q38222370-F6CDBE5B-57BC-4500-A41C-CE63A3751D27Q38353580-FE68F6D6-F45E-4AF4-A7E3-96914B67367CQ38376983-5802C82A-98DA-406A-AEFD-B0C3F8E7D04AQ38540467-F7F4D59E-8C7D-4868-B535-C603C601CF84Q38561441-936DC1CD-6BF3-4B04-A59E-766BE8553976Q38676886-06FA91B9-F6CE-4B8C-8149-CEBAD6BAFC1EQ38905198-8ED3C085-69AA-4DFE-917D-28A01F188604Q39000103-1AE72BD0-8CD1-4040-9547-83DD533C05C3Q39059489-F27E3223-4388-4931-8EAF-84B3536388E9Q40108118-0ABE1412-E153-4969-903C-910959C4152FQ40503940-0857619F-1CEC-46C5-BF62-4BDE63F4F9A8Q41108172-F64122AF-B688-4919-98C0-4ADD8ADBC110Q42381020-167AF005-9DC7-4BAE-B30C-61009D0C3D5FQ42389709-F28A3F8E-26A6-4F09-A3D0-C8E6308E1CEDQ47672621-74B1B61E-0E68-454E-8F7E-7B4FBDFD38E4Q49613444-8F9551C9-1CD6-42CE-A2BC-D7C9DF25A2BCQ51507722-7FA99C90-837A-4406-8B8D-1D5EAE3EB81DQ52878564-7052D641-5972-4B41-B9C5-351E740F9F59Q54266346-8F3BDB4F-B315-403B-A23E-98D066614976Q55002696-3D297CF5-0C84-4169-81ED-54512884135DQ58697544-6B9CE3F3-9AE3-4AC0-8317-D36307D1E34E
P2860
Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Use of procalcitonin for the d ...... in Acute Heart Failure) trial
@ast
Use of procalcitonin for the d ...... in Acute Heart Failure) trial
@en
type
label
Use of procalcitonin for the d ...... in Acute Heart Failure) trial
@ast
Use of procalcitonin for the d ...... in Acute Heart Failure) trial
@en
prefLabel
Use of procalcitonin for the d ...... in Acute Heart Failure) trial
@ast
Use of procalcitonin for the d ...... in Acute Heart Failure) trial
@en
P2093
P2860
P50
P921
P356
P1476
Use of procalcitonin for the d ...... in Acute Heart Failure) trial
@en
P2093
Alan H B Wu
Alan Maisel
Andreas Bergmann
Christian Mueller
Christopher Hogan
Garret Terracciano
Gerasimos S Filippatos
James McCord
Judd Landsberg
Lori B Daniels
P2860
P304
P356
10.1093/EURJHF/HFR177
P577
2012-02-02T00:00:00Z